The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic Society International ...

Hypothyroidism related to immunotherapy in elderly adults: Analysis of a Colombian oncology cohort. Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

The American Academy of Pediatrics presents updated guidance for the treatment of children with atopic dermatitis (AD).

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...